Table 2 Current pharmacological treatment, according to the presence of extra-articular symptoms
N = 1115 | ExtRA (n = 261) | No ExtRA (n = 854) | p |
|---|---|---|---|
scDMARD | |||
Methotrexate + Leflunomide | 39 (14.9%) | 142(16.6%) | 0.518 |
Methotrexate | 169 (64.8%) | 572 (67%) | 0.505 |
Leflunomide | 77 (29.5%) | 301(35.2%) | 0.086 |
Antimalarials | 27 (10.3%) | 119 (13.9%) | 0.133 |
Sulfasalazine | 13 (5%) | 42(4.9%) | 0.967 |
Azathioprine | 7 (2.7%) | 3 (0.4%) | 0.002 |
Cyclosporine | 2 (0.8%) | 2(0.2%) | 0.235 |
tsDMARDt (tofacitinib) | 2(0.8%) | 7(0.8%) | > 0.999 |
bDMARD | |||
Anti-TNF | 63 (24.1%) | 159 (18.6%) | 0.051 |
Etanercept | 22 (8.4%) | 44(5.2%) | 0.049 |
Certolizumab | 4 (1.5%) | 13 (1.5%) | > 0.999 |
Golimumab | 9 (3.4%) | 28 (3.3%) | 0.894 |
Infliximab | 16 (6.1%) | 32(3.7%) | 0.097 |
Adalimumab | 12 (4.6%) | 42(4.9%) | 0.833 |
Non-anti TNF | 45 (17.2%) | 131(15.3%) | 0.461 |
Abatacept | 15 (5.7%) | 57 (6.7%) | 0.594 |
Tocilizumab | 15 (5.7%) | 40 (4.7%) | 0.488 |
Rituximab | 15 (5.7%) | 34 (4%) | 0.223 |
Others | |||
NSAID | 38 (14.6%) | 63 (7.4%) | < 0.001 |
Glucocorticoids | 141 (54%) | 367(43%) | 0.002 |